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OBJECTIVE — Flicker light–induced retinal vasodilation may reﬂect endothelial function in
the retinal circulation. We investigated ﬂicker light–induced vasodilation in individuals with
diabetes and diabetic retinopathy.
RESEARCH DESIGN AND METHODS — Participants consisted of 224 individuals
with diabetes and 103 nondiabetic control subjects. Flicker light–induced retinal vasodilation
(percentage increase over baseline diameter) was measured using the Dynamic Vessel Analyzer.
Diabetic retinopathy was graded from retinal photographs.
RESULTS — Mean  SD age was 56.5  11.8 years for those with diabetes and 48.0  16.3
yearsforcontrolsubjects.Meanarteriolarandvenulardilationafterﬂickerlightstimulationwere
reduced in participants with diabetes compared with those in control subjects (1.43  2.10 vs.
3.462.36%,P0.001forarteriolarand2.832.10vs.3.981.84%,P0.001forvenular
dilation). After adjustment for age, sex, diabetes duration, fasting glucose, cholesterol and tri-
glyceridelevels,currentsmokingstatus,systolicbloodpressure,anduseofantihypertensiveand
lipid-lowering medications, participants with reduced ﬂicker light–induced vasodilation were
morelikelytohavediabetes(oddsratio19.7[95%CI6.5–59.1],P0.001and8.14[3.1–21.4],
P  0.001, comparing lowest vs. highest tertile of arteriolar and venular dilation, respectively).
Diabetic participants with reduced ﬂicker light–induced vasodilation were more likely to have
diabeticretinopathy(2.2[1.2–4.0],P0.01forarteriolardilationand2.5[1.3–4.5],P0.004
for venular dilation).
CONCLUSIONS — Reduced retinal vasodilation after ﬂicker light stimulation is indepen-
dently associated with diabetes status and, in individuals with diabetes, with diabetic retinopa-
thy. Our ﬁndings may therefore support endothelial dysfunction as a pathophysiological
mechanism underlying diabetes and its microvascular manifestations.
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iabetes affects more than 240 mil-
lion individuals worldwide, and di-
abetic retinopathy is the leading
cause of blindness in the working-age
population in most developed countries
(1). There is increasing recognition that
early endothelial dysfunction plays a key
role in the pathogenesis of diabetes (2)
and the development of subsequent mi-
crovascular complications (3). In support
of endothelial dysfunction in diabetic ret-
inopathy(4)arestudiesshowingrelation-
ships of diabetic retinopathy with
cardiovascular diseases, including stroke,
coronary heart disease, and heart failure,
independent of traditional risk factors
(5–7). Diabetic retinopathy has also been
linked with subclinical manifestations of
vascular diseases such as coronary artery
calciﬁcation and cardiac remodeling (5).
However, clinical and epidemiological
studies have not found consistent associ-
ations of serum markers of endothelial
dysfunction (e.g., soluble vascular adhe-
sion molecule-1) with diabetic retinopa-
thy, with some reporting positive
associations (8,9), but others not ﬁnding
any (10,11).
The response of retinal vessels to dif-
fuse luminance ﬂicker can be measured
noninvasively (12) and may reﬂect endo-
thelial function of the retinal circulation
because it has been demonstrated that ni-
tric oxide is released in the retinal vascu-
laturewhenitisstimulatedbyﬂickerlight
(13). One recent study showed that indi-
viduals with diabetes and diabetic reti-
nopathy have reduced ﬂicker-induced
retinalvasodilationbutdidnotcontrolfor
concomitantriskfactorsincludinghyper-
glycemia, hypertension, and diabetes du-
ration (14). In our current study, we
sought to clarify whether ﬂicker light–
induced vasodilation is impaired in pa-
tients with diabetes and in those with
diabetic retinopathy, signs independent
of major risk factors.
RESEARCH DESIGN AND
METHODS— We conducted a hospi-
tal-based clinical study between October
2006 and April 2008, prospectively re-
cruiting 224 Caucasian/white partici-
pants with diabetes (85 with type 1
diabetes and 139 with type 2 diabetes)
from the diabetic eye clinics at the Inter-
national Diabetes Institute (Melbourne,
VIC, Australia) and 103 white nondia-
beticcontrolsubjectsfromthegeneraleye
clinics at the Royal Victorian Eye and Ear
Hospital (Melbourne, VIC, Australia).
Control subjects were consecutive pa-
tients seen at the hospital among individ-
uals without diabetes and any retinal or
eye pathological conditions. Individuals
were excluded from participation if they
were aged 70 years, were of nonwhite
ethnic background, had a history of epi-
lepsy or glaucoma, had previous vitreal
surgery, and/or had a cataract on
examination.
All participants and control subjects
had a standardized clinical examination,
measurement of blood chemistry, retinal
photographs, and assessment of ﬂicker-
induced vasodilation using the Dynamic
Vessel Analyzer (DVA; IMEDOS, Jena,
Germany). Tenets of the Declaration of
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view board approval was granted, and
written informed consent was obtained
from all participants.
Flicker light–induced retinal
vasodilation
The DVA measures retinal vessel dilation
in response to diffuse luminance ﬂicker
(12). Examination was conducted in a
half-light room. The participant focused
on the tip of a ﬁxation bar within the ret-
inal camera while the fundus was exam-
ined under green light. An arteriole and
venule segment between one-half and
twodiscdiametersfromthemarginofthe
optic disc were selected. The mean diam-
eters of the arterial and venous vessel seg-
ments were calculated and recorded
automatically. Baseline vessel diameter
was measured for 50 s, followed by a
provocation with ﬂicker light of the same
wavelength for 20 s and then a nonﬂicker
period for 80 s. This measurement cycle
was repeated twice, with a total duration
of 350 s/eye. When the eye blinked or
moved, the system automatically stopped
themeasurementandrestarteditoncethe
vessel segments were automatically
reidentiﬁed.
Retinal arteriolar and venular dilation
in response to ﬂicker light was calculated
automaticallybytheDVAsoftware.Itwas
represented as an average increase in the
vessel diameter in response to the ﬂicker
lightduringthethreemeasurementcycles
and was deﬁned as the percent increase
relative to the baseline diameter size.
Measurement of static retinal vessel
diameter
In addition to quantifying the ﬂicker-
induced vasodilation, we assessed overall
static arteriolar and venular diameter us-
ing a computer-assisted program. Details
of the digital image preparation are de-
scribed elsewhere (15). In brief, diame-
ters of the largest six arterioles and
venules passing through the circular zone
between one-half and one disc diameter
away from the optic disc margin were
summarized as the central retinal arterio-
lar equivalent and central retinal venular
equivalent using the Parr-Hubbard for-
mula further modiﬁed by Knudtson and
colleagues (15).
Assessment of diabetes
Fasting blood samples were drawn from
participants at suburban pathology cen-
tersformeasurementoffastingbloodglu-
cose level within 2 weeks of their eye
testing. All participants with diabetes
were patients recruited from the diabetic
eye clinics and were managed with oral
hypoglycemic mediations and/or insulin.
Control subjects (individuals without
diabetes) had conﬁrmed nondiabetic
status based on a lack of history of dia-
betes and fasting glucose 7.0 mmol/l
(126 mg/dl).
Assessment of diabetic retinopathy
Inparticipantswithdiabetes,diabeticret-
inopathy was graded from fundus photo-
graphs at the Centre for Eye Research
Australia, by graders masked to clinical
details. For each eye, a retinopathy sever-
ity score was assigned based on modiﬁca-
tion of the Airlie House Classiﬁcation
system (16). For our analysis, levels 10,
11, and 12 were deﬁned as no diabetic
retinopathy, 14 to 20 as minimal nonpro-
liferativediabeticretinopathy(NPDR),31
and 41 as early to moderate NPDR, and
51–80 as severe NPDR (proliferative dia-
betic retinopathy).
Assessment of other risk factors
A detailed questionnaire was used to ob-
tain participant information, including
past medical history, current cigarette
smoking, and the use of antihypertensive
and lipid-lowering medications. Hyper-
tension was deﬁned as systolic blood
pressure (SBP) 140 mmHg, diastolic
blood pressure (DBP) 90 mmHg, or
current use of antihypertensive medica-
tions. Dyslipidemia was deﬁned as cho-
lesterol5.5mmol/lortriglyceride2.0
mmol/l or current use of lipid-lowering
medications. Height and weight were
measured to determine BMI. Fasting
blood samples were drawn from partici-
pants at suburban pathology centers for
fasting blood glucose level, cholesterol
and triglyceride levels, and A1C within 2
weeks of their eye testing.
Statistical analysis
We compared ﬂicker light–induced reti-
nalvasodilationbetweenindividualswith
diabetes and control subjects and in indi-
viduals with diabetes between those with
and without DR. Flicker-induced arterio-
lar/venular dilation was analyzed as per-
centincreaseoverbaselinediameter,both
asacontinuousmeasureandincategories
(tertiles). Data from both right and left
eyes were used. Multiple logistic regres-
sion models were constructed using the
generalized estimating equation models
to account for correlation between the
right and left eyes and to assess the odds
of diabetes (vs. nondiabetic control sub-
jects) or diabetic retinopathy (vs. no dia-
betic retinopathy among subjects with
diabetes),comparingthelowerversusup-
per tertiles of ﬂicker light–induced arte-
riolar and venular dilation. In addition,
multiple linear regression models were
used to estimate the mean difference in
arteriolar and venular dilation. We ini-
tially adjusted for age, sex, and fasting
blood glucose level (model 1) and further
adjusted for duration of diabetes (in anal-
ysisofdiabeticpatients),useofantihyper-
tensive and lipid-lowering medications,
current smoking status, SBP, and choles-
terol and triglyceride levels (model 2).
AnalyseswereperformedinStata(version
10.1; StataCorp, College Station, TX).
RESULTS— Selected characteristics
ofnormalcontrolsubjects(n103),par-
ticipants with diabetes (n  224, 85 with
type 1 and 139 with type 2 diabetes), and
those with (n  144) and without (n 
80) diabetic retinopathy are shown in Ta-
ble 1. Mean  age was 56.5  11.8 years
insubjectswithdiabetesand48.016.3
years in control subjects. The proportion
of men was similar for participants with
diabetes (41.6%) and control subjects
(39.4%). Compared with nondiabetic
control subjects, participants with diabe-
tes were less likely to be current smokers
but had higher BMI and were more likely
to have hypertension, dyslipidemia,
lower DBP, and lower total cholesterol
levels. Compared with those with type 1
diabetes, individuals with type 2 diabetes
wereolder,hadgreaterBMI,butashorter
durationofdiabetes,andweremorelikely
to have hypertension and dyslipidemia
(data not shown). In participants with di-
abetes, those with diabetic retinopathy
had a longer duration of diabetes, had
higher SBP, and were more likely to have
hypertension. In addition, participants
with diabetes had wider static arteriolar
diameter than nondiabetic control sub-
jects,whereasthosewithdiabeticretinop-
athy had wider retinal venules than those
without (Table 1).
Flicker light–induced retinal vasodi-
lation was reduced in participants with
diabetes compared with that in control
subjects (Table 2). Flicker light–induced
arteriolar dilation was 1.43  2.10% in
participants with diabetes and 3.46 
2.36% in normal control subjects (P 
0.001 after adjustment for age, sex, fast-
ing glucose, cholesterol and triglyceride
levels, use of antihypertensive and lipid-
lowering medications, and current smok-
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not signiﬁcantly different by type of diabe-
tes: 1.57% in those with type 1 and 1.24%
in those with type 2 diabetes (P  0.98).
Flicker light–induced venular dilation was
2.83  2.10% in individuals with diabetes
and 3.98  1.84% in normal control sub-
jects (P  0.001 after multivariable adjust-
ment) and again was not signiﬁcantly
differentbytypeofdiabetes:2.84%inthose
with type 1 and 2.83% in those with type 2
diabetes (P  0.99).
Table 1—Participant characteristics (age-adjusted means and proportions) comparing participants with diabetes and normal control subjects,
and, among participants with diabetes, those with and without diabetic retinopathy
Control
subjects
Diabetic
subjects P*
Diabetic
retinopathy
No
retinopathy P†
n 103 224 144 80
Sex (% male) 39.4 41.6 0.74 37.5 49.2 0.09
Current smoking (%) 20.7 7.3 0.002 10.2 2.4 0.05
Hypertension (% present) 14.2 56.3 0.001 63.8 42.1 0.006
Dyslipidemia (% present) 7.0 48.1 0.001 49.9 44.1 0.46
Age (years) 48.0 56.5 0.001 57.4 54.8 0.08
Diabetes duration (years) — 16.2 18.7 11.9 0.001
SBP (mmHg) 129.5 127.1 0.22 128.5 124.4 0.03
DBP (mmHg) 80.2 75.9 0.001 75.7 76.4 0.55
BMI (kg/m
2) 26.3 30.3 0.001 30.5 29.7 0.38
A1C (%) 5.5 7.9 0.001 8.0 7.7 0.27
Glucose (mmol/l) 5.0 9.2 0.001 9.5 8.5 0.07
Cholesterol (mmol/l) 5.4 4.6 0.001 4.6 4.7 0.28
Triglyceride (mmol/l) 1.6 0.25 1.5 1.6 0.45
Dynamic retinal vessel dilation
Maximal arteriolar dilation 3.33 1.50 0.001 1.21 1.81 0.006
Maximal venular dilation 3.91 2.88 0.001 2.57 3.21 0.003
Static retinal vessel diameter
CRAE (m) 146.0 149.8 0.007 150.8 149.4 0.35
CRVE (m) 220.7 222.2 0.52 225.8 218.9 0.006
Dataaremeansunlessstatedotherwise.Meansandproportionsareadjustedforage(settomeanageof53.8yearsold),exceptforage.*Comparingthosewithdiabetic
subjects and normal control subjects, adjusted for age. †Comparing those with and without diabetic retinopathy in those with diabetes, adjusted for age. CRAE,
central retinal arteriolar equivalent; CRVE, central retinal venular equivalent.
Table 2—Mean differences in ﬂicker light–induced vasodilation between participants with diabetes and normal control subjects and by grades
of diabetic retinopathy severity in participants with diabetes
Groups n Mean dilation
Age- and sex-adjusted Multivariable adjusted*
Mean difference (95% CI) P Mean difference (95% CI) P
Arteriolar
Control subjects 103 3.46 (Reference) (Reference)
Diabetic patients 224 1.43 1.87 (1.43 to 2.31) 0.001 1.58 (1.05 to 2.11) 0.001
Type 1 diabetes 1.57 1.99 (1.46 to 2.52) 0.001 1.71 (1.10 to 2.32) 0.001
Type 2 diabetes 1.24 1.78 (1.29 to 2.27) 0.001 1.48 (0.90 to 2.07) 0.001
Diabetic retinopathy severity
None 1.76 (Reference) (Reference)
Minimal NPDR 1.39 0.37 (0.29 to 1.03) 0.28 0.53 (0.16 to 1.22) 0.13
Early-moderate NPDR 1.01 0.75 (0.23 to 1.28) 0.005 0.85 (0.29 to 1.40) 0.003
Severe NPDR 1.24 0.51 (0.15 to 1.16) 0.13 0.58 (0.12 to 1.28) 0.10
Venular
Control subjects 3.98 (Reference) (Reference)
Diabetic patients 2.83 0.98 (0.57 to 1.39) 0.001 1.07 (0.56 to 1.57) 0.001
Type 1 diabetes 2.84 1.11 (0.62 to 1.61) 0.001 1.36 (0.78 to 1.94) 0.001
Type 2 diabetes 2.83 0.88 (0.42 to 1.34) 0.001 0.83 (0.27 to 1.38) 0.004
Diabetic retinopathy severity
None 3.19 (Reference) (Reference)
Minimal NPDR 2.94 0.49 (0.10 to 1.09) 0.10 0.10 (0.60 to 0.79) 0.78
Early-moderate NPDR 2.40 1.11 (0.63 to 1.58) 0.001 0.67 (0.11 to 1.23) 0.02
Severe NPDR 2.32 1.16 (0.55 to 1.77) 0.001 0.65 (0.06 to 1.35) 0.07
Dataare%.*Adjustmentforage,sex,fastingcholesterolandtriglyceridelevels,useofantihypertensiveandlipid-loweringmedications,currentsmokingstatus,and
fasting glucose (for analysis of diabetic retinopathy severity).
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adjustment, individuals with reduced
ﬂicker light–induced vasodilation were
more likely to have diabetes (odds ratios
[ORs]19.7and8.1,comparingthelowest
versus the highest tertile of arteriolar and
venular dilation, respectively). Among
participants with diabetes, those with re-
duced ﬂicker induced–dilation were
more likely to have diabetic retinopathy
(ORs 2.2 and 2.5, respectively, for arte-
riolar and venular dilation) (Table 4).
These associations persisted after further
adjustmentforstaticarteriolar/venulardi-
ameters (Tables 3 and 4, model 3).
The distribution of diabetic retinopa-
thy severity was not signiﬁcantly different
between those with type 1 and type 2 di-
abetes (P  0.57, data not shown). How-
ever, the association of reduced ﬂicker
light–induced vasodilation with diabetic
retinopathy was stronger in participants
with type 1 diabetes (arteriolar dilation
OR 3.1 [95% CI 1.1–8.5]; venular dila-
tion OR 3.8 [95% CI 1.4–10.0]) com-
pared with those with type 2 diabetes
(arteriolar dilation OR 1.8 [95% CI 0.8–
4.0]; venular dilation OR 1.3 [95% CI
0.6–3.1]), although the interaction with
type of diabetes was not statistically sig-
niﬁcant (P value for interaction term: P 
0.50 for arteriolar dilation and P  0.09
for venular dilation).
CONCLUSIONS— In this study, we
demonstratedareductioninﬂickerlight–
induced retinal arteriolar and venular di-
lation in individuals with diabetes
compared with nondiabetic control sub-
jects and, among individuals with diabe-
tes, in those with retinopathy signs.
Importantly, we showed that these asso-
ciations were independent of major risk
factors for either diabetes or diabetic ret-
inopathy and independent of static mea-
surements of retinal arterioles and
venular diameters.
Therehavebeentwopreviousstudies
for comparison (14,17). Garhofer et al.
(17) examined 26 healthy control sub-
jects and 26 individuals with type 1 dia-
betes who had none or minimal NPDR
and were not receiving antihypertensive
treatment, whereas Mandecka et al. (14)
examined 240 individuals with diabetes
(68 with type 1 and 172 with type 2 dia-
betes) and 58 control subjects. Both
showed reduced ﬂicker light vasodilation
in those with diabetes (compared with
those without diabetes). Furthermore,
Mandecka et al. also demonstrated a re-
duction in ﬂicker light vasodilation with
increasing diabetic retinopathy severity,
while controlling only for age, sex, and
use of antihypertensive medications. We
have now shown that the relationship of
ﬂicker light–induced vasodilation and
both diabetes and diabetic retinopathy
are independent of major confounders
and risk factors for diabetic retinopathy,
including duration of diabetes and glyce-
mic control.
Retinal neuronal stimulation by
ﬂicker light results in retinal vessel dila-
tion. This response probably reﬂects en-
dothelial function (14), given the
documented role of nitric oxide in this
ﬂickering light–induced vasodilation
(13,18,19). In a study by Dorner et al.
(13), N
G-monomethyl-L-arginine, an in-
hibitor of nitric oxide synthase, blunted
Table 3—Associations between reduced ﬂicker-induced arteriolar and venular dilation and diabetes
Dynamic ﬂicker-induced dilation Diabetes
n* Tertiles Range (%) % Model 1 P Model 2 P Model 3 P
Arteriolar
173 Lowest 0.6 89.0 12.6 (5.54–28.7) 0.001 19.7 (6.53–59.1) 0.001 19.5 (6.30–60.2) 0.001
182 Middle 0.7–2.9 76.9 7.76 (3.75–16.1) 0.001 11.2 (4.29–29.3) 0.001 11.16 (4.22–29.5) 0.001
178 Highest 3.0 45.5 1.00 (Reference) — 1.00 (Reference) — 1.00 (Reference) —
Venular
178 Lowest 2.1 86.5 4.67 (2.19–9.96) 0.001 8.14 (3.09–21.4) 0.001 8.03 (3.05–21.2) 0.001
177 Middle 2.2–3.7 67.8 1.17 (0.64–2.14) 0.62 1.43 (0.66–3.13) 0.37 1.40 (0.64–3.08) 0.40
182 Highest 3.8 56.0 1.00 (Reference) — 1.00 (Reference) — 1.00 (Reference) —
Data are ORs (95% CI) unless indicated otherwise. Model 1: adjusted for age, sex, and fasting blood glucose level. Model 2: adjusted for covariates in model 1 plus
diabetes duration, use of antihypertensive and lipid-lowering medications, current smoking status, SBP, and fasting cholesterol and triglyceride levels. Model 3:
adjusted for covariates in model 2 plus static retinal arteriolar or venular diameter. *n indicates number of eyes.
Table 4—Associations between reduced ﬂicker-induced arteriolar and venular dilation and diabetic retinopathy
Dynamic ﬂicker-induced dilation Diabetic retinopathy
n* Tertiles Range (%) % Model 1 P Model 2 P Model 3 P
Arteriolar
121 Lowest 0.3 60.3 2.52 (1.46–4.36) 0.001 2.19 (1.19–4.03) 0.01 2.02 (1.09, 3.74) 0.03
127 Middle 0.4–1.8 55.9 1.92 (1.13–3.27) 0.02 1.88 (1.04–3.41) 0.04 1.81 (0.99, 3.31) 0.05
127 Highest 1.9 43.3 1.00 (Reference) — 1.00 (Reference) — 1.00 (Reference) —
Venular
120 Lowest 1.7 67.5 3.14 (1.82–5.45) 0.001 2.45 (1.33–4.49) 0.004 2.41 (1.30, 4.67) 0.005
122 Middle 1.8–3.3 53.3 1.54 (0.91–2.60) 0.11 1.33 (0.75–2.38) 0.33 1.36 (0.75, 2.44) 0.31
134 Highest 3.4 39.6 1.00 (Reference) — 1.00 (Reference) — 1.00 (Reference) —
Data are ORs (95% CI) unless indicated otherwise. Model 1: adjusted for age, sex, and fasting blood glucose level. Model 2: adjusted for covariates in model 1 plus
diabetes duration, use of antihypertensive and lipid-lowering medications, current smoking status, SBP, and fasting cholesterol and triglyceride levels. Model 3:
adjusted for covariates in model 2 plus static retinal arteriolar or venular diameter. *n indicates number of eyes.
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healthyindividuals.Inaddition,impaired
response to ﬂicker light stimulation in in-
dividuals with hypertension could be re-
stored by angiotensin II subtype 1
receptor blockade (20). However, this
ﬁnding has been documented only in in-
dividuals without diabetes. It was hy-
pothesized previously that the decreased
endothelial dysfunction in subjects with
diabetesisassociatedwithimpairednitric
oxideactionbecauseofitsinactivationre-
sulting from increased oxidative stress
and that abnormal nitric oxide metabo-
lismisrelatedtoadvanceddiabeticmicro-
vascular complications (21). This
hypothesis is supported by recent data
demonstrating similar retinal arteriolar
and venular dilation after a single sublin-
gualdoseof0.8mgnitroglycerinbetween
20 patients with insulin-treated diabetes
with no or only mild NPDR and 20
healthy age-matched control subjects
(22). However, it is becoming increas-
inglyclearthatneuronalcellsoftheretina
are also affected by diabetes, resulting in
dysfunction and degeneration (23), and
diabetic retinopathy is a disease of both
retinal neurons and microcirculation
(24). Because retinal blood ﬂow is cou-
pled with neuronal activity (25), reduced
ﬂicker light–induced vasodilation can
thus also reﬂect neurodegeneration
(17,24).
In our study, signiﬁcantly reduced
ﬂicker light–induced vasodilation was
observed in diabetic subjects with dia-
betic retinopathy compared with those
without diabetic retinopathy. This rela-
tionship appeared to be stronger among
individuals with type 1 diabetes than
among those with type 2 diabetes, given
the similar distribution of diabetic reti-
nopathy severity between the two
groups. This observation could be due
to longer diabetes duration in those
with type 1 diabetes (mean 22.1 years
for type 2 diabetes vs. 12.6 years for
type 2 diabetes), resulting in possibly a
greater level of impairment of retinal
vascular autoregulation (26), endothe-
lial damage (26), or neurodegeneration
(17,24). Alternatively, the underlying
mechanisms of diabetic retinopathy
may be different in type 1 and type 2
diabetes.
The strengths of this study include
quantitative measures of retinal vasodi-
lation after ﬂicker light stimulation, as-
sessment of diabetic retinopathy from
fundus photographs using standardized
grading protocols, and one researcher
(T.T.N.) performing all DVA measure-
ments. Limitations of this study should
also be noted. First, the cross-sectional
nature of the study provides no tempo-
ral information on the associations re-
ported. Second, our ﬁndings are only
applicable to individuals with diabetes
whoareaged70years.Third,wehave
no measurement of retinal neuronal
function. Thus, further longitudinal
studies are needed to ascertain cause
and effect and to correlate ﬂicker-
induced vasodilation with retinal neu-
ronal functions using tests such as
electroretinography.
In summary, we demonstrated a re-
duction in ﬂicker light–induced retinal
vasodilation in individuals with diabetes
and, among those with diabetes, in those
with retinopathy signs. These ﬁndings
further support the concept that early en-
dothelial dysfunction is a likely key
pathophysiological mechanism that un-
derlies diabetes and its microvascular
complications.
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